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Generating T cells  
for immunotherapy
Adoptive transfer of T lymphocytes 
engineered to achieve tumor specificity 
through the genetic insertion of either T 
cell receptors or chimeric antigen receptors 
(CARs) allows remarkable control of dis-
seminated tumors across multiple phase 
I/II clinical studies in the academic setting 
(1, 2). Some of these approaches are now 
further developed in multicenter studies 
supported by pharmaceutical companies. 
Manufacturing of engineered T cells is a 
key element for the realistic execution of 
multicenter clinical studies and for the 
future use of these cells in the clinical prac-
tice. Manufacturing of T cells is generally 
centralized to ensure reproducibility and 
aims at implementing standard operating 
procedures with minimized complexity. 
To this end, peripheral blood mononuclear 
cells (PBMCs) are frequently preferred for 
generating engineered T cell products. 
PBMCs are indeed readily obtained by 
gradient centrifugation and contain all cir-
culating T cell subsets, from naive T cells 
to memory T cells, susceptible to effective 
transduction by viral vectors encoding the 
transgene following activation with CD3/
CD28 crosslinking antibodies and cyto-
kines. Starting from PBMCs, T cell prod-
ucts can be obtained within two weeks of 
ex vivo culture, a time schedule compat-
ible with an effective clinical application 
in many patients with refractory and resis-
tant malignancies.
To select or not to select — 
that is the question
In the current issue of the JCI, Klebanoff 
et al. highlight that the complexity of the 
immune system may not be easily reca-
pitulated using simplified approaches and 
that a more sophisticated manipulation 
of T cell subsets within the infused T cell 
products may affect clinical outcome (3). 
This last observation stems from a long 
history of mouse model studies showing 
how less-differentiated T cell subsets from 
naive T cells (TN cells) to central memory T 
cells (TCM cells) display superior antitumor 
capacity and persistence compared with 
more-differentiated T cells, such as effec-
tor-memory T cells (TEM cells) or effector T 
cells (TE cells) (4). More recently, another 
subset of memory T cells, identified as T 
stem cell memory cells (TSCM cells), claims 
properties superior even to TN and TCM 
cells (5). Clinical observations corroborate 
the relevance of preserving primitive T 
cell subsets within infused T cell products 
to ensure T cell expansion and potentially 
long-term engraftment (6, 7).
The composition of T cell subsets 
found in PBMCs of cancer patients is large-
ly affected by several factors, including 
age, disease, and type of chemotherapy 
treatments received before blood procure-
ment. All these factors contribute to cre-
ating very heterogeneous T cell products 
when whole PBMCs are used as a starting 
material. One could argue that the high 
response rate in both adult and pediatric 
patients with acute lymphoblastic leuke-
mia infused with CD19-specific CAR–T 
cells supports the use of PBMCs as a start-
ing source of T cells, regardless of their 
heterogeneity, as they contain all the T cell 
subsets needed for an effective immune 
response (2, 8, 9). However, a more pre-
cise composition of the T cell products 
and in particular the enrichment in T cells 
with the highest potential for engraft-
ment may become particularly relevant in 
other clinical settings, specifically in most 
solid tumors, in which the response rate to 
adoptive T cell therapies is currently sig-




How can we preserve more immature and 
bona fide highly functional T cell subsets 
within infusion products without applying 
complex standard operating procedures? 
Activation, genetic manipulation, and ex 
vivo expansion of T cells inevitably induce 
their differentiation. This differentiation 
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The clinical application of T cell immunotherapy depends on ex vivo 
modification and expansion of T cells for adoptive transfer. In preclinical 
models, the use of a purified, naive T cell subset enhances persistence 
and antitumor immunity; however, the majority of clinical studies rely 
on modification of mixed populations of T cells that contain only a small 
subset of highly functional T cells with less-differentiated phenotype. In this 
month’s issue of the JCI, Klebanoff and colleagues uncover a Fas-mediated 
interaction between naive T cells and antigen-experienced T cells that 
drives differentiation and impairs adoptive immunotherapy. Further, they 
show that blockade of Fas signaling enhances antitumor immunity and 
increases survival in a mouse model of melanoma. Their work supports a 
growing body of evidence that the use of naive T cells enhances the efficacy 
of adoptive T cell therapy and suggests a new therapeutic strategy for 
preserving less-differentiated T cell populations.
pathways that promote the precocious dif-
ferentiation of TN cells. They found indeed 
that TMEM cells mediate the differentia-
tion of TN cells through Fas ligand (FasL) 
expressed by activated TMEM cells interact-
ing with Fas on activated TN cells. Prevent-
ing Fas-FasL interaction by FasL-blocking 
antibodies or genetic ablation of Fas on TN 
cells restores the primitive TSCM and TCM 
cell populations in the TN cell progeny. In 
addition, provision of FasL alone is suf-
ficient to promote TN cell precocious dif-
ferentiation in the absence of TMEM cells. 
Fas-FasL interaction induces the extrinsic 
apoptosis pathway via caspase 8. Interest-
ingly, the precocious differentiation of TN 
cells induced by TMEM cells does not induce 
a cell death pathway, but instead depends 
on activation of Akt signaling and meta-
bolic modulation. TN cells expanded with 
TMEM cells show elevated activation of Akt 
and glycolytic activity, a phenomenon that 
can be recapitulated by the addition of 
FasL. Inhibition of Akt activation reverses 
the precocious differentiation, raising the 
possibility of pharmacologic modulation 
of this process.
Conclusions and future 
directions
It remains unknown whether there is cross-
talk among the mixed populations of TEM, 
TCM, and TSCM cells present in the infused 
products. Moreover, since CD4+ T cells 
are also present in unfractionated PBMCs 
and play a role in promoting the survival 
of engineered T cells (14), determining 
whether this quorum-sensing phenom-
enon exists within the CD4 subset would 
greatly benefit the manufacturing of T cell 
modulation in TN cells, downregulating 
the expression of lymphoid-homing che-
mokine receptors (CD62L and CCR7) and 
memory-associated transcription factors. 
Overall, this leads to a reduction in antitu-
mor efficacy of TN cell progeny expanded 
in the presence of TMEM cells.
This observation suggests that, to 
preserve the intrinsic properties of TN cell 
progenies, engineered T cells should be 
generated exclusively from TN cells select-
ed from PBMCs (Figure 1). This mirrors the 
approach proposed by other investigators 
who optimized the selection of TCM cells 
for engineering purposes (13). However, 
the mechanistic model proposed by Kle-
banoff et al. still keeps open the possibility 
of manipulating the culture conditions of 
unselected PBMCs to disrupt the signaling 
process can be stalled through manipula-
tions during the expansion phase using 
cytokines, such as IL-7 and IL-15 instead 
of IL-2, to preserve more TSCM cells (7, 10). 
In addition, activation of the Wnt-signal-
ing pathway has been implied to delay T 
cell differentiation (11, 12). However, in 
the current issue of the JCI, Klebanoff et 
al. further elucidate the complexity of T 
cell interactions in vitro showing in both 
mouse and human that memory T cells 
(TMEM cells) actively induce “precocious 
differentiation” of TN cells when they are 
activated and expanded together. In the 
presence of TMEM cells, TN cell progenies 
acquire enhanced effector functions, such 
as expression of granzyme B and the ability 
to produce IFN-γ upon restimulation. TMEM 
cells also mediate global transcriptional 
Figure 1. Schematic representation of the 
generation of engineered T cells for adoptive 
immunotherapy. Unfractionated PBMCs con-
taining TN, TSCM,TCM, and TEM cells are frequently 
used as starting material to generate gene-
manipulated T cell products for adoptive immu-
notherapy in cancer patients. To preserve more 
immature T cell subsets, the manipulation of 
culture conditions by using different cocktails of 
cytokines or by activating or inhibiting specific 
pathways has been developed. In the current 
issue of the JCI, Klebanoff et al. suggest that the 
selection of TN cells from PBMCs may represent 
the most effective strategy to preserve more 
immature T cell subsets in T cell products.
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